STUDY TO DETERMINE THE POTENTIAL DDIS WHEN THE DACLATASVIR/ASUNAPREVIR/BMS-791325 THREE DRUG ANTIVIRAL COMBINATION TABLET (FDC) IS COADMINISTERED WITH A COCKTAIL OF CYTOCHROME P450 (CYP) PROBE SUBSTRATES AND TRANSPORTER PROBE SUBSTRATES (DIGOXIN AND PRAVASTATIN) IN HEALTHY SUBJECTS: